Issues of imatinib and pregnancy outcome

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 7, Issue 10, 2009, Pages 1050-1058

  Apperley, Jane ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Chemotherapy; Chronic myelogenous leukemia; CML; Fertility; Imatinib; Pregnancy; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; BUSULFAN; HYDROXYUREA; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONGENITAL MALFORMATION; EMBRYO DEVELOPMENT; FEMALE FERTILITY; FERTILITY; HUMAN; LEUKAPHERESIS; MALE FERTILITY; NIDATION; NONHUMAN; ORGANOGENESIS; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; QUALITY OF LIFE; REVIEW;

EID: 74049088287     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2009.0069     Document Type: Review

References (65)

1. Soriano P. Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev 1994;8:1888-1896.
2. Soriano P. The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development 1997;124:2691-2700.
3. Hoch RV, Soriano P. Roles of PDGF in animal development. Development 2003;130:4769-4784.
4. Tybulewicz VL, Crawford CE, Jackson PK, et al. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 1991;65:1153-1163.
5. Mauduit C, Hamamah S, Benahmed M. Stem cell factor/c-kit system in spermatogenesis. Hum Reprod Update 1999;5:535-545.
6. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358-3363.
7. Novartis Pharmaceuticals Corporation. Gleevec Full Prescribing Information. Updated, May 2009. East Hanover, New Jersey. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/ gleevec-tabs.pdf. Accessed November 4, 2009.
8. Nurmio M, Toppari J, Zaman F, et al. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat. Int J Androl 2007;30:366-376.
9. Basciani S, De Luca G, Dolci S, et al. Platelet-derived growth factor receptor beta-subtype regulates proliferation and migration of gonocytes. Endocrinology 2008;149:6226-6235.
10. Nurmio M, Kallio J, Toppari J, Jahnukainen K. Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis. Reprod Toxicol 2008;25:442-446.
11. Seshadri T, Seymour JF, McArthur GA. Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome. N Engl J Med 2004;351:2134-2135.
12. Christopoulos C, Dimakopoulou V, Rotas E. Primary ovarian insufficiency associated with imatinib therapy. N Engl J Med 2008;358:1079-1080.
13. Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 2003;40(2 Suppl 3):21-25.
14. Ault P, Kantarjian H, O'Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006;24:1204-1208.
15. Ramasamy K, Hayden J, Lim Z, et al. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol 2007;137:374-375.
16. Breccia M, Cannella L, Montefusco E, et al. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases. Leuk Res 2008;32:519-520.
17. Meera V, Jijina F, Shrikande M, et al. Twin pregnancy in a patient of chronic myeloid leukemia on imatinib therapy. Leuk Res 2008;32:1620-1622.
18. Buyukbayrak EE, Ergen B, Karsidag YK, et al. Pregnancy complicated with chronic myelogeneous leukemia (CML) successfully treated with imatinib: a case report. Arch Gynecol Obstet 2008;278:161-163.
19. Yilmaz M, Demirhan O, Kucukosmanoglu E, et al. Pregnancy in patients with chronic myeloid leukemia treated with imatinib. Leuk Lymphoma 2007;48:2454-2456.
20. Koh LP, Kanagalingam D. Pregnancies in patients with chronic myeloid leukemia in the era of imatinib. Int J Hematol 2006;84:459-462.
21. Ali R, Ozkalemkas F, Ozcelik T, et al. Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res 2005;29:971-973.
22. Ali R, Ozkalemkas F, Ozkocaman V, et al. Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of rhe literature. Jpn J Clin Oncol 2004;34:215-217.
23. Choudhary DR, Mishra P, Kumar R, et al. Pregnancy on imatinib: fatal outcome with meningocele. Ann Oncol 2006;17:178-179.
24. Prabhash K, Sastry PS, Biswas G, et al. Pregnancy outcome of two patients treated with imatinib. Ann Oncol 2005;16:1983-1984.
25. AlKindi S, Dennison D, Pathare A. Imatinib in pregnancy. Eur J Haematol 2005;74:535-537.
26. Heartin E, Walkinshaw S, Clark RE. Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib. Leuk Lymphoma 2004;45:1307-1308.
27. Garderet L, Santacruz R, Barbu V, et al. Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib. Haematologica 2007;92:e9-10.
28. Suppiah R, Kalaycio M. Successful outcome of pregnancy in a patient with chronic myelogenous leukemia exposed to imatinib during the first trimester. Leuk Lymphoma 2006;47:1149-1150.
29. Skoumalova I, Vondrakova J, Rohon P, et al. Successful childbirth in a patient with chronic myelogenous leukemia treated with imatinib mesylate during early pregnancy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008;152:121-123.
30. Dolai TK, Bhargava R, Mahapatra M, et al. Is imatinib safe during pregnancy? Leuk Res 2009;33:572-573.
31. Sora F, De Matteis S, Bajer J, et al. Persistence of molecular remission throughout pregnancy in CML after imatinib. Leuk Res 2009;33:e6-e7.
32. Klamova H, Markova M, Moravcova J, et al. Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery. Leuk Res 2009;33:1567-1569.
33. Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood 2008;111:5505-5508.
34. Calzolari E, Bianchi F, Dolk H, Milan M. Omphalocele and gastroschisis in Europe: a survey of 3 million births 1980-1990. EUROCAT Working Group. Am J Med Genet 1995;58:187-194.
35. Soriano P. The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development 1997;124:2691-2700.
36. Robertson SC, Tynan J, Donoghue DJ. RTK mutations and human syndromes: when good receptors turn bad. Trends Genet 2000;16:368.
37. Russell MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 2007;27:241-243.
38. Ali R, Ozkalemkas F, Kimya Y, et al. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet 2009;280:169-175.
39. Kronenberger R, Schleyer E, Bornhauser M, et al. Imatinib in breast milk. Ann Hematol 2009;88:1265-1266.
40. Doll DC, Ringenberg QS, Yarbro JW. Antineoplastic agents and pregnancy. Semin Oncol 1989;16:337-346.
41. Rahman ME, Ishikawa H, Watanabe Y, Endo A. Carpal and tarsal bone development is highly sensitive to three antiproliferative teratogens in mice. Reprod Toxicol 1996;10:485-489.
42. Delmer A, Rio B, Bauduer F, et al. Pregnancy during myelosuppressive treatment for chronic myelogenous leukemia. Br J Haematol 1992;82:783-784.
43. Patel M, Dukes IA, Hull JC. Use of hydroxyurea in chronic myeloid leukemia during pregnancy: a case report. Am J Obstet Gynecol 1991;165:565-566.
44. Tertian G, Tchernia G, Papiernik E, Elefant E. Hydroxyurea and pregnancy. Am J Obstet Gynecol 1992;166(6 Pt 1):1868.
45. Jackson N, Shukri A, Ali K. Hydroxyurea treatment for chronic myeloid leukaemia during pregnancy. Br J Haematol 1993;85:203-204.
46. Sylvester RK, Lobell M, Teresi ME, et al. Excretion of hydroxyurea into milk. Cancer 1987;60:2177-2178.
47. Caplan SN, Coco FV, Berkman EM. Management of chronic myelocytic leukemia in pregnancy by cell pheresis. Transfusion 1978;18:120-124.
48. Broccia G, Casula P, Andria M. Chronic myelocytic leukemia in pregnancy: report of a case treated with leukapheresis. Tumori 1984;70:371-374.
49. Fitzgerald D, Rowe JM, Heal J. Leukapheresis for control of chronic myelogenous leukemia during pregnancy. Am J Hematol 1986;22:213-218.
50. Bazarbashi MS, Smith MR, Karanes C, et al. Successful management of Ph chromosome chronic myelogenous leukemia with leukapheresis during pregnancy. Am J Hematol 1991;38:235-237.
51. Ali R, Ozkalemkas F, Ozkocaman V, et al. Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature. Jpn J Clin Oncol 2004;34:215-217.
52. Girling JC, de Swiet M. Thromboembolism in pregnancy: an overview. Curr Opin Obstet Gynecol 1996;8:458-463.
53. Riyazi N, Leeda M, de Vries JI, et al. Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. Eur J Obstet Gynecol Reprod Biol 1998;80:49-54.
54. Ginsberg JS, Bates SM. Management of venous thromboembolism during pregnancy. J Thromb Haemost 2003;1:1435-1442.
55. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001;119(1 Suppl):122S-131S.
56. Maher JE, Owen J, Hauth J, et al. The effect of low-dose aspirin on fetal urine output and amniotic fluid volume. Am J Obstet Gynecol 1993;169:885-888.
57. Owen J, Maher JE, Hauth JC, et al. The effect of low-dose aspirin on umbilical artery Doppler measurements. Am J Obstet Gynecol 1993;169:907-911.
58. Martinelli P, Martinelli V, Agangi A, et al. Interferon alfa treatment for pregnant women affected by essential thrombocythemia: case reports and a review. Am J Obstet Gynecol 2004;191:2016-2020.
59. Milano V, Gabrielli S, Rizzo N, et al. Successful treatment of essential thrombocythemia in a pregnancy with recombinant interferon-alpha 2a. J Matern Fetal Med 1996;5:74-78.
60. Pardini S, Dore F, Murineddu M, et al. Alpha 2b-interferon therapy and pregnancy - report of a case of essential thrombocythemia. Am J Hematol 1993;43:78-79.
61. Petit JJ, Callis M, Fernandez DS. Normal pregnancy in a patient with essential thrombocythemia treated with interferon-alpha 2b. Am J Hematol 1992;40:80.
62. Pons JC, Lebon P, Frydman R, Delfraissy JF. Pharmacokinetics of interferon-alpha in pregnant women and fetoplacental passage. Fetal Diagn Ther 1995;10:7-10.
63. Goh HG, Kim YJ, Kim DW, et al. Previous best responses can be reachieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leuk Lymphoma 2009;50:944-951.
64. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58-60.
65. Delmer A, Rio B, Bauduer F, et al. Pregnancy during myelosuppressive treatment for chronic myelogenous leukemia. Br J Haematol 1992;82:783-784.